Hosted on MSN

Pfizer’s new phase 1 study: A potential breakthrough for kidney disease treatment

Pfizer Inc (PFE) announced an update on their ongoing clinical study. Pfizer Inc. has launched a Phase 1 clinical study titled A Phase 1, Randomized, Multi-Center, Double-Blind, Sponsor Open, ...
BioSpace

JPM26: Pfizer Fast-Tracks Obesity Programs in Race Against Patent Cliff

Facing the loss of exclusivity on key products, Pfizer has pulled forward its lead obesity asset into Phase III and targeted a 2028 launch. CEO Albert Bourla explained the pharma's strategy at J.P.
MedCity News

Pfizer’s Appetite for More Obesity Meds Leads to $150M Deal for Oral GLP-1 Drug From China

Fresh off the acquisition of metabolic medicines developer Metsera, Pfizer is again turning to dealmaking to expand its obesity drug pipeline, this time picking up an experimental oral drug that could ...

Pfizer Advances PF-07248144 With New Drug–Interaction Study, Signaling Quiet Pipeline Progress

Pfizer Inc (PFE) announced an update on their ongoing clinical study.

JPM26: Pfizer’s Metsera deal supercharges its obesity strategy

Pfizer is gearing up for a consumer-driven obesity drug market, drawing parallels to the demand surge it experienced with the launch of Viagra (sildenafil), CEO Albert Bourla said at the 44th Annual ...
Hosted on MSN

Pfizer’s Fosun-partnered GLP-1 drug more aligned with orforglipron, Leerink says

Leerink analyst David Risinger notes that Pfizer (PFE) disclosed on December 9, 2025, that it entered into an exclusive global collaboration and license agreement with Fosun Pharma’s subsidiary ...